ICMJE DISCLOSURE FORM

Date: 03/14/23

Your Name: Pooja Yesantharao

Manuscript Title: Lymphedema Surgery in Breast Cancer Patients: A Systematic Review of Preoperative Evaluation and

Surgical Planning

Manuscript number (if known): ABS-22-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
	Time frame: Since the initial planning of the work					
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone				
	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone				
3	Royalties or licenses	XNone				
4	Consulting fees	XNone				

5	Payment or honoraria for lectures, presentations,	XNone					
	speakers bureaus,						
	manuscript writing or						
	educational events						
6	Payment for expert testimony	XNone					
7	Support for attending	X None					
′	meetings and/or travel						
	meetings and, or traver						
8	Patents planned, issued or	X None					
0	pending						
	, F						
9	Participation on a Data	X None					
9	Safety Monitoring Board or	XNOTIE					
	Advisory Board						
10	Leadership or fiduciary role in other board, society,	X None					
10							
	committee or advocacy						
	group, paid or unpaid						
11	Stock or stock options	XNone					
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None					
	services						
13	Other financial or non- financial interests	XNone					
Dاح	Please summarize the above conflict of interest in the following box:						
ric							
	None.						

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: 03/14/23

Your Name: Dung Nguyen

Manuscript Title: Lymphedema Surgery in Breast Cancer Patients: A Systematic Review of Preoperative Evaluation and

Surgical Planning

Manuscript number (if known): ABS-22-50

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone			
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	Stanford Cancer Center Clinical Innovation Fund Fibralign Corporation	\$50,000 - Shifting the Paradigm: Establishing a Comprehensive, Multidisciplinary Lymphedema Prevention Program \$250,000 - Prospective evaluation of the BioBridge Scaffold as an adjunct to Vascularized Lymph Node Transplant for Upper Extremity Lymphedema		
3	Royalties or licenses	X None			

4	Consulting fees	X None	
4	consulting rees	xnone	
5	Payment or honoraria for	X None	
3	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
,	meetings and/or travel		
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non- financial interests	XNone	

Please summarize the above conflict of interest in the following box:

Dr. Dung H. Nguyen has grant funding related to lymphedema surgery and improving outcomes in lymphedema patients from Stanford Cancer Center Clinical Innovation Fund and Fibralign Corporation, but she has not received any support for the current manuscript.

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.